Is AEterna Zentaris Inc. (AEZS) a Stock to Watch After Gaining 19.88% This Week?

AEterna Zentaris Inc. (AEZS) stock is up 19.88% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

AEterna Zentaris Inc. has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on AEZS!

See Full AEZS Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With AEZS Stock Today?

AEterna Zentaris Inc. (AEZS) stock is higher by 2.24% while the S&P 500 has fallen -0.04% as of 9:43 AM on Friday, Nov 24. AEZS has gained $0.04 from the previous closing price of $1.89 on volume of 1,179 shares. Over the past year the S&P 500 is up 13.10% while AEZS has fallen -48.94%. AEZS lost -$4.81 per share in the over the last 12 months.

More About AEterna Zentaris Inc.

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland. Click Here to get the full Stock Report for AEterna Zentaris Inc. stock.